fezolinetant
Veozah
Pharmaceutical company: Astellas Pharma
Pharmacologic classification: Neurokinin 3 receptor antagonist
Therapeutic classification: Menopause drug
AVAILABLE FORMS
Tablets: 45 mg
INDICATIONS AND DOSAGES
Moderate to severe vasomotor symptoms due to menopause
Adults: 45 mg PO once daily.
CONTRAINDICATIONS AND CAUTIONS
- Contraindicated in patients with known cirrhosis, severe kidney impairment or kidney failure.
- Safety and efficacy in children haven't been established.
- Dialyzable drug: Unknown.
PREGNANCY-LACTATION-REPRODUCTION
- There are no data on the risks associated with the use of this drug during pregnancy.
- It's unknown if this drug appears in human milk.
INTERACTIONS
Drug-drug.
CYP1A2 inhibitors (cimetidine, ciprofloxacin, fluvoxamine): May increase fezolinetant level. Use together is contraindicated.
ADVERSE REACTIONS
CNS: insomnia.
GI: abdominal pain, diarrhea.
Hepatic: transaminase elevation.
Musculoskeletal: back pain.
Other: hot flash.
Reactions in bold italics are life-threatening.
Released: September 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer
perfluorohexyloctane
Miebo
Pharmaceutical company: Bausch and Lomb
Pharmacologic classification: Semifluorinated alkane
Therapeutic classification: Miscellaneous ophthalmic drug
AVAILABLE FORMS
Ophthalmic solution: 100% multi-dose bottles
INDICATIONS AND DOSAGES
Dry eye disease
Adults: Instill one drop q.i.d. into affected eye(s).
CONTRAINDICATIONS AND CAUTIONS
- Safety and effectiveness in patients younger than age 18 have not been established.
- Dialyzable drug: Unknown.
PREGNANCY-LACTATION-REPRODUCTION
- There are no adequate studies during pregnancy. Use cautiously during pregnancy.
- There are no data on the presence of this drug in human milk, its effects on breastfed infants, or on milk production. Use cautiously during breastfeeding.
INTERACTIONS
None reported by the manufacturer.
ADVERSE REACTIONS
EENT: blurred vision, conjunctival redness.
Reactions in bold italics are life-threatening.
Released: September 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer